Overview

Sequential, Related Donor Partial Liver Transplantation Followed by Bone Marrow Transplantation for Hepatocellular Carcinoma (HCC)

Status:
Withdrawn

Trial end date:
2018-01-03

Target enrollment:

Participant gender:

Summary

This trial is a phase II, single arm, open-label, single center study to assess a reduced-intensity conditioning regimen, bone marrow transplantation and high dose PTCy in recipients of a partial liver allograft from a Human Leukocyte Antigen (HLA)-matched or -haploidentical living related donor in patients with HCC. The primary objective of this trial is to characterize recurrence-free survival at 1 year following bone marrow transplantation among recipients of prior partial liver transplantation from the same donor.

Phase:

Phase 2

Details

Lead Sponsor:

Sidney Kimmel Comprehensive Cancer Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Collaborator:

Fibrolamellar Cancer Foundation

Treatments:

Antilymphocyte Serum
Cyclophosphamide
Fludarabine
Fludarabine phosphate
Lenograstim
Liver Extracts
Mesna
Mycophenolate mofetil
Mycophenolic Acid
Prednisone
Tacrolimus